Imperial College London
Portrait Picture

ProfessorAlanWinston

Faculty of Medicine, Department of Infectious Disease

Professor of Genito-Urinary Medicine
 
 
 
//

Contact

 

+44 (0)20 3312 1603a.winston

 
 
//

Location

 

Winston Churchill WingSt Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Raffi:2020:jac/dkaa056,
author = {Raffi, F and Gaultier, A and Pozniak, A and Molina, J-M and Jessen, H and Antinori, A and Soria, A and Cavellec, M and Le, Thuaut A and Ningre, M and de, Wit S},
doi = {jac/dkaa056},
journal = {J Antimicrob Chemother},
pages = {1618--1622},
title = {Five-year follow-up of patients enrolled in the NEAT 001/ANRS 143 randomized clinical trial: NEAT 001/ANRS 143 LONG TERM study.},
url = {http://dx.doi.org/10.1093/jac/dkaa056},
volume = {75},
year = {2020}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BACKGROUND: Few long-term data are available in subjects having initiated ART with an NRTI-sparing regimen. OBJECTIVES: Outcomes of subjects enrolled in the NEAT 001/ANRS 143 randomized clinical trial (comparing ritonavir-boosted darunavir + raltegravir versus ritonavir-boosted darunavir + tenofovir disoproxil fumarate/emtricitabine) were retrospectively collected, through anonymized electronic case report forms, up to 6 years post-enrolment. METHODS: The last NEAT 001 visit (Week 96) was conducted in 745/805 randomized subjects (363/401 ritonavir-boosted darunavir + raltegravir and 382/404 ritonavir-boosted darunavir + tenofovir disoproxil fumarate/emtricitabine). Of these, 430 were enrolled in NEAT 001/ANRS 143 LONG TERM (NLT) study (201 raltegravir, 229 tenofovir disoproxil fumarate/emtricitabine), with a median follow-up of 44.4 months. RESULTS: During NLT follow-up, the proportion of AIDS, non-AIDS events, virological rebound and serious adverse events, discontinuation for virological failure and for adverse events did not differ between groups; discontinuations for virological failure since NEAT 001 inclusion were more frequent in subjects with baseline CD4 <200 cells/mm3 (11.9% versus 5.3%; P = 0.077). At last follow-up, a quarter of subjects (22.2% for ritonavir-boosted darunavir + raltegravir and 29.7% for ritonavir-boosted darunavir + tenofovir disoproxil fumarate/emtricitabine) were still receiving their initial regimen. Integrase inhibitor exposure was not associated with weight gain (P = 0.48), while tenofovir disoproxil fumarate exposure was associated with a trend to higher creatinine increase (P = 0.067). CONCLUSIONS: After a median of 5.6 years, subjects initiating ritonavir-boosted darunavir + raltegravir or ritonavir-boosted darunavir + tenofovir disoproxil fumarate/emtricitabine experienced few serious clinical adverse events. Most discontinuations were for reasons unrelated
AU  - Raffi,F
AU  - Gaultier,A
AU  - Pozniak,A
AU  - Molina,J-M
AU  - Jessen,H
AU  - Antinori,A
AU  - Soria,A
AU  - Cavellec,M
AU  - Le,Thuaut A
AU  - Ningre,M
AU  - de,Wit S
DO  - jac/dkaa056
EP  - 1622
PY  - 2020///
SP  - 1618
TI  - Five-year follow-up of patients enrolled in the NEAT 001/ANRS 143 randomized clinical trial: NEAT 001/ANRS 143 LONG TERM study.
T2  - J Antimicrob Chemother
UR  - http://dx.doi.org/10.1093/jac/dkaa056
UR  - https://www.ncbi.nlm.nih.gov/pubmed/32211883
VL  - 75
ER  -
Download